It’s only a small-scale project, but it’s exciting to see new funding models being tried out for drug development.
Here on Techdirt we’ve been pretty scathing about the way that Big Pharma develops drugs — often poorly — and then uses patent monopolies to keep prices so high that only rich Westerners can afford them. Of course, it’s easy to complain about the flaws of the current approach, but are there any alternatives? We’ve already covered one — using prizes – and now Carl Levinson points us to another potentially powerful approach: crowdsourcing. It’s already been adopted by ‘Project Marilyn’ to develop a patent-free anti-cancer drug:
The campaign will fund a xenograft experiment, which is the next step in developing the promising anti-cancer compound “9DS”. This experiment needs to be completed before 9DS can move on to clinical trials.
Here are some more details of both the drug and the project:
The drug candidate 9DS was developed at the University of Maryland. The last work done on the drug showed that it had activity against cancer competitive with leading cancer drugs such as taxol. Moreover, 9DS is also likely to have lower side effects than most chemotherapies, since a related compound, SJG-136, seems to have low side effects in early clinical trials.
Project Marilyn involves: production of more 9DS, and submitting 9DS to a xenograft study (‘curing cancer in mice’). This is the next step in drug development and an important one on the way to doing clinical (human) studies. The process we’re seeking to fund should take approximately 6 months. If we receive more funding, we will add stretch goals, such as further preclinical experiments on 9DS, development 9DS analogs, or other exciting anti-cancer ideas.
Of course, even if enough money is raised — at the time of writing, just over a quarter of the crowdfunding target has been pledged — there’s still much more work to be done before the drug can be sold to the public. An article in the Times of San Diego explains what will happen next:
The Latest on: Patent-free drug
via Google News
The Latest on: Patent-free drug
- FDA Joins Effort to Curb Drug Patent Abuseson August 4, 2022 at 10:12 am
FDA and the USPTO hope to promote competition by challenging strategies designed to block timely approval of generics and biosimilars.
- U.S. Prescription Drug Market Often Isn’t Competitive: Case Of Biosimilarson August 3, 2022 at 7:28 am
A regularly heard talking point is that follow-on drugs, such as biosimilars and generics, will bring down prices through competition. But, they don’t invariably do so. PBMs may favor more expensive ...
- Despite $5B sales for Keytruda, Merck hits two PhIII snags as it continues to build its multibillion-dollar drugon August 3, 2022 at 7:25 am
Continuing on its quest to grow Keytruda’s blockbuster status ahead of a 2028 patent cliff, Merck reported today that Keytruda has missed in two indications — as a first-line therapy in combination ...
- Pharmalittle: AbbVie wins court opinion on Humira patent thickets; Alnylam heart disease drug succeeds in closely watched trialon August 3, 2022 at 6:28 am
A U.S. appeals court panel declined to revive a lawsuit that accused AbbVie of using a so-called patent thicket to forestall competition for Humira.
- This Arthritis Drug Deserves Its Aggressive Patent Protectionon August 3, 2022 at 4:08 am
US as Humira. The principal patent on Humira expired in 2016, but AbbVie has obtained some 132 more, of which the great majority were granted in 2014 or later. Most of these newer patents relate to ...
- Tonix Pharmaceuticals Announces Issuance of U.S. Patent Covering Potentiated Intranasal Oxytocin (TNX-1900) for the Treatment of Painon August 1, 2022 at 4:03 am
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, announced today that the United States Patent and Trademark Office (USPTO) issued U.S. Patent 11,389,473 ...
- Texas Tech pharmacist receives patent for repurposing antipsychotic drug to treat canceron July 29, 2022 at 1:04 pm
A Texas Tech University Health Science Center pharmacist has received a patent for repurposing antipsychotic drugs to treat cancers.
- Cheap copies of GSK's HIV prevention drug could be ready in 2026on July 28, 2022 at 6:04 pm
British drugmaker GSK has struck a deal to allow low-cost generic versions of its long-acting HIV preventive medicine to be used in the developing world, including sub-Saharan Africa where the virus ...
- Bausch Health Provides Update Following Oral Order in XIFAXAN Patent Litigationon July 28, 2022 at 12:45 pm
Bausch Health Companies Inc. (NYSE/TSX: BHC), and its gastroenterology business Salix Pharmaceuticals, today announced the U.S. District Court of Delaware issued an Oral Order in the matter of Salix ...
- GSK's Generic low-cost HIV prevention drug expected to be ready in 2026on July 28, 2022 at 10:55 am
Low-cost preventative HIV medication may be ready as early as 2026, as British pharmaceutical company GSK strikes a deal allowing developing countries access to generic versions.
via Bing News